General Commentary
Published on 23 Jun 2022
Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
in General Cardiovascular Medicine
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.916705
- 2,352 views


